IR Insights: Recapping our Q1 2024 Earnings Report
Earlier today, Moderna reported financial results and provided business updates for the first quarter of 2024. We provided the investor community with an update on our business and clinical updates across our respiratory, oncology, rare, latent and other portfolios.
Members of our executive team sat down to provide more insight into our financial performance, upcoming late-stage pipeline milestones, and the exciting clinical and corporate developments happening at Moderna. Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel, President Stephen Hoge, and CFO Jamey Mock:
Forward-Looking Statements
This post and accompanying video contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s expected product sales in 2024 and trends informing Moderna’s 2024 sales outlook; Moderna's anticipated approval and launch of its RSV vaccine in 2024, market dynamics, and its competitive profile; Moderna's 2024 financial framework and anticipated performance, including expected revenues; anticipated milestones for Moderna's pipeline programs in 2024; and Moderna’s plans to move INT forward in additional indications. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.